Skip to main content

UM SOM Researchers Awarded Grant to Use Innovative Alternative to Autopsies to Better Understand Child Mortality

June 29, 2016

Kathleen Neuzil, MD, MPH and Dean E. Albert Reece, MD, PhD, MBA

Research in Mali to Illuminate Causes of Childhood Death

Kathleen Neuzil, MD, MPH, director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM), and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that CVD has been awarded a large grant from the Bill & Melinda Gates Foundation for research that will help determine why so many children under five are dying in the world’s poorest countries. The grant will fund use of an innovative alternative to traditional autopsy known as minimally invasive tissue sampling. The technique, which involves the collection of tissue samples with fine needles, allows researchers to quickly identify the cause of death, and help illuminate ways to save lives and improve the health of children in these vulnerable areas.

The grant, awarded to CVD in May, will support work at CVD’s center in Bamako, Mali. It is one of the first three sites to be chosen, joining Soweto, South Africa and Manhiça, Mozambique.

This work is part of a larger effort led by Emory University and funded by the Bill & Melinda Gates Foundation to create a network of up to 25 disease surveillance sites known as the Child Health and Mortality Prevention Surveillance network (CHAMPS). The Gates Foundation has committed up to $75 million overall to establish the first six surveillance sites in south Asia and sub-Saharan Africa over the next three years. The program is a long-term project, and is expected to last for 20 years.

Dr. Kotloff and Dr. SowThe lead researchers on the grant are Karen Kotloff, MD, Professor of Pediatrics and Head of the Division of Infectious Disease and Tropical Pediatrics at the University of Maryland School of Medicine (UM SOM) and Samba Sow, MD, MS, Adjunct Professor of Medicine at UM SOM and Director General of CVD-Mali.

“We are very excited to be part of this important project,” said Dr. Kotloff. “We think this can really help us understand the causes of child mortality. CVD-Mali has an outstanding track record conducting infectious disease research that directly benefits the health and well-being of Malian citizens. The tremendous support of the Malian government has made this possible. It is our hope that CHAMPS data will facilitate efforts to diminish the unacceptably high child mortality rates in Mali.”

The problem of child mortality is enormous. In 2015, nearly 6 million children died before reaching their fifth birthday—16,000 every day, most in the poorest countries of the world.

A key part of the CHAMPS project is the minimally invasive tissue sampling, which can serve as a substitute for autopsy. When a child dies in the developing world, performing a traditional autopsy is difficult. Often patients die far from a hospital, where there is a shortage of equipment and trained personnel. More importantly, in many cultures autopsies are not accepted, particularly for children, and parents and relatives are not comfortable having them done. Minimally invasive tissue sampling addresses these limitations and concerns. Such sampling is easier to perform, less expensive, and more acceptable culturally: fine needles are inserted into the body, retrieving small amounts of organ tissue, including lung, liver, heart and brain. This tissue is then examined to pinpoint potential causes of death. By establishing cause of death, researchers can better understand which knowledge gaps most need to be addressed, which interventions will save the most lives, and which diseases require a novel approach to prevention and cure.

Dr. Kotloff also said that training local medical personnel in Mali and elsewhere will build a medical research infrastructure able to support not only the goals of the CHAMPS study, but also the needs of local health agencies.

CVD-Mali was founded in 2001 as a partnership between the Ministry of Health of Mali and CVD. The mission of CVD-Mali is to prevent, control and treat endemic and epidemic infectious diseases in Mali, in particular those that are vaccine-preventable. CVD-Mali is dedicated to quantifying disease burden, testing the safety, immunogenicity and efficacy of relevant new vaccines and training Malian vaccinologists. CVD-Mali has a full range of laboratory, research and clinical trial capabilities.

CVD-Mali is part of the Malian Ministry of Health, and the data from CHAMPS will help the country, Dr. Sow said. “CHAMPS gives us an unprecedented opportunity to uncover information about life-threatening childhood illnesses that can lead to better recognition, prevention, and treatment,” he said.

“For the past 40 years, the Center for Vaccine Development has been working to save the lives of children around the world,” said UM SOM Dean E. Albert Reece, MD, PhD, MBA, who is also the vice president for Medical Affairs, University of Maryland, and the John Z. and Akiko K. Bowers Distinguished Professor. “This new grant allows them to continue to pursue this worthiest of efforts, in an innovative way.”

CHAMPS press release:

About the University of Maryland School of Medicine

The University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine. The School of Medicine is the founding school of the University of Maryland and is an integral part of the 11-campus University System of Maryland. Located on the University of Maryland’s Baltimore campus, the School of Medicine works closely with the University of Maryland Medical Center and Medical System to provide a research-intensive, academic and clinically based education. With 43 academic departments, centers and institutes and a faculty of more than 3,000 physicians and research scientists plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S. with top-tier faculty and programs in cancer, brain science, surgery and transplantation, trauma and emergency medicine, vaccine development and human genomics, among other centers of excellence. The School is not only concerned with the health of the citizens of Maryland and the nation, but also has a global presence, with research and treatment facilities in more than 35 countries around the world.

About the Center for Vaccine Development

The CVD at the University of Maryland School of Medicine works nationally and internationally to prevent disease and save lives through the development and delivery of vaccines. As an academic research center, CVD is engaged in the full range of vaccinology, including basic science research, vaccine development, pre-clinical and clinical evaluation, and post-marketing field studies.


Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559

Contact Media Relations
(410) 706-5260

Related stories